For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the projected market size of the neuromyelitis optica spectrum disorder industry, and what is its expected CAGR?
The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), rising awareness and early diagnosis, rising therapeutic options and FDA approvals, growing research and development activities, and rising clinical trials for novel therapies.
The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, increasing healthcare expenditure, rising investments in research and development, increasing prevalence of autoimmune diseases, increasing clinical trials for NMOSD therapies, and growing demand for personalized medicine. Major trends in the forecast period include advancements in precision medicine, collaboration & partnerships, technological innovations, integration of AI & big data in research, and a shift towards home-based treatments.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22072&type=smp
What external factors are influencing the neuromyelitis optica spectrum disorder market’s growth momentum?
The increasing prevalence of multiple sclerosis is expected to propel the growth of the neuromyelitis optica spectrum disorder market going forward. Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system, causing inflammation, nerve damage, and neurological symptoms. The increasing prevalence of multiple sclerosis is due to improvising diagnostic techniques, environmental influences, and genetic predisposition. Advancements in medical imaging, such as MRI, have allowed for earlier and more accurate diagnoses, leading to an apparent rise in cases. As more individuals are diagnosed with MS, there is a heightened awareness of neurological autoimmune diseases, leading to improved diagnostic methods and greater recognition of neuromyelitis optica spectrum disorder. For instance, in May 2024, according to the Multiple Sclerosis Trust, a UK-based national charity, the UK sees approximately 7,100 new multiple sclerosis cases annually, and some 135 persons are diagnosed with MS each week. Therefore, the increasing prevalence of multiple sclerosis drives the growth of the neuromyelitis optica spectrum disorder market.
What are the major market segments driving the growth of the neuromyelitis optica spectrum disorder industry?
The neuromyelitis optica spectrum disorder market covered in this report is segmented –
1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies
2) By Diagnosis: Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Others Diagnosis
3) By Treatment Type: C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies: Relapsing NMOSD with AQP4-IgG, Monophasic NMOSD with AQP4-IgG, Severe Optic Neuritis with AQP4-IgG, Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG
2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG), Seronegative NMOSD, Idiopathic NMOSD Cases, NMOSD Associated With Other Autoimmune Disorders
View The Full Market Report:
How are emerging trends transforming the neuromyelitis optica spectrum disorder market dynamics?
Major companies operating in the neuromyelitis optica spectrum disorder market are focusing on developing innovative products, such as long-acting complement inhibitors, to enhance treatment efficacy and improve patient outcomes. Long-acting complement inhibitors are treatments that suppress the complement system for an extended duration, preventing inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD). They help minimize relapses and support long-term disease control. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical industry, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This approval marks Ultomiris as the first and only long-acting C5 complement inhibitor available for NMOSD treatment. The decision was based on the Phase III CHAMPION-NMOSD trial, where Ultomiris demonstrated a 98.6% reduction in relapse risk over 73 weeks compared to a placebo. Trial participants experienced no relapses, and no new safety concerns were identified.
Who are the key market players contributing to the growth of the neuromyelitis optica spectrum disorder industry?
Major companies operating in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics
Which regions are leading the growth of the neuromyelitis optica spectrum disorder market globally?
North America was the largest region in the neuromyelitis optica spectrum disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromyelitis optica spectrum disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Neuromyelitis Optica Spectrum Disorder Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22072
Need Customized Data On Neuromyelitis Optica Spectrum Disorder Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22072&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
